Loading
A phase 2 trial of Pembrolizumab in colorectal cancer, run by CytoDyn, Inc., active and no longer recruiting.
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen is a phase 2 interventional study registered as NCT06699836 by CytoDyn, Inc., with 66 participants enrolled, started 2025-06-16 and due to reach its primary completion in 2028-01. Interventions recorded: 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab. Conditions listed: Metastatic Colorectal Cancer (mCRC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/